A new treatment option for opioid-induced constipation has been recommended for use by the NHS in England.
Naloxegol (Moventig) has been recommended as an option for treating opioid-induced constipation in adults whose symptoms have not adequately responded to laxatives.
The National Institute for Health and Clinical Excellence published final guidance today on naloxego, which is a pegylated form of naloxol that is manufactured by AstraZeneca.
In its pegylated form – attached to a molecule of polyethylene glycol – it selectively antagonises peripheral opioid receptors to relieve constipation.
NICE noted that inadequate response to laxatives was defined as symptoms of at least moderate severity while taking at least one laxative class for a minimum of four days during the last two weeks.
The most commonly reported adverse reactions to naloxegol are abdominal pain, diarrhoea, nausea, headache and flatulence.
The majority of gastrointestinal adverse reactions are graded as mild to moderate, and occur early in treatment and resolve with continued treatment.
The list price for naloxegol, which has been agreed by the Department of Health, is £55.20 per 30-tablet pack of 12.5mg or 25mg film-coated tablets.
The recommended dose is 25mg taken orally once daily or 12.5mg for people with renal insufficiency.